To assess the prevalence of modest (<10-fold) decreases in baseline non-nucleoside reverse transcriptase inhibitor (NNRTI) susceptibility and their impact on virological response to NNRTI-containing triple therapy in drug-naive individuals.
Methods
Baseline HIV resistance phenotype, genotype and response to therapy were examined retrospectively for all antiretroviral-naive individuals initiating therapy with two nucleoside analogues and an NNRTI in British Columbia, Canada, between 05/1997 and 08/1999 (n=279), followed until July 31 2001. Time to viral suppression (first of at least two consecutive plasma viral loads <400 copies HIV RNA copies/ml) and viral rebound (to ≥400 copies/ml after first pVL <400 copies HIV RNA copies/ml), were estimated by Kaplan-Meier methods. Multivariate analyses were performed using Cox proportional hazards regression.
Results
Nevirapine was the most commonly prescribed NNRTI (96%). Four- to 10-fold decreased susceptibility to NNRTIs was observed in >30% of untreated individuals at baseline, an observation strongly driven by decreased susceptibility to delavirdine (22.4%). A >10-fold decrease in susceptibility to any NNRTI was observed only rarely (<2%). There was no association between four- and 10-fold decreased baseline susceptibility to NNRTIs and virological outcome (P>0.05). In multivariate analyses, the strongest predictors of poor virological response to NNRTI-based therapy were baseline plasma viral load and the proportion of time on therapy in the first year of follow-up. There was no relationship between the presence of previously reported mutations associated with decreased NNRTI susceptibility (at codons 135 and 283 in HIV reverse transcriptase) and virological response.
Conclusions
These data suggest that the clinically significant level of resistance to NNRTIs, particularly nevirapine, in drug-naive individuals is likely greater than four- to 10-fold.
References
1.
KuritzkesD.R.Clinical significance of drug resistance in HIV-1 infection. AIDS1996; 10(Suppl. 5): S27–S31.
HirschM.S., ConwayB., D'AquilaR.T., JohnsonV.A., Brun-VezinetF., ClotetB., DemeterL.M., HammerS.M., JacobsenD.M., KuritzkesD.R., LovedayC., MellorsJ.W., VellaS., & RichmanD.D.Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. Journal of the American Medical Association1998; 279: 1984–1991.
4.
LittleS.J., DaarE.S., D'AquilaR.T., KeiserP.H., ConnickE., WhitcombJ.M., HellmannN.S., PetropoulosC.J., SuttonL., PittJ.A., RosenbergE.S., KoupR.A., WalkerB., & RichmanD.D.Reduced antiretroviral drug susceptibility among patients with primary HIV infection. Journal of the American Medical Association1999; 282: 1142–1149.
5.
BodenD., HurleyA., ZhangL., CaoY., GuoY., JonesE., TsayJ., IpJ., FarthingC., LimoliK., ParkinN., & MarkowitzM.HIV-1 drug resistance in newly infected individuals. Journal of the American Medical Association1999; 282: 1135–1141.
SalomonH., WainbergM.A., BrennerB., QuanY., RouleauD., CoteP., LeBlancR., LefebvreE., SpiraB., TsoukasC., SekalyR.P., ConwayB., MayersD., & RoutyJ.P.Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS2000; 14: F17–F23.
8.
WegnerS.A., BrodineS.K., MascolaJ.R., TaskerS.A., ShafferR.A., StarkeyM.J., BarileA., MartinG.J., AronsonN., EmmonsW.W., StephanK., BloorS., VingerhoetsJ., HertogsK., & LarderB.Prevalence of genotypic and phenotypic resistance to antiretroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS2000; 14: 1009–1015.
9.
AlexanderC.S., DongW., ChanK., JahnkeN., O'ShaughnessyM.V., MoT., PiasecznyM.A., MontanerJ.S., & HarriganP.R.HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS2001; 15: 601–607.
10.
LittleS.J., HolteS., RoutyJ.P., DaarE.S., MarkowitzM., CollierA.C., KoupR.A., MellorsJ.W., ConnickE., ConwayB., KilbyM., WangL., WhitcombJ.M., HellmannN.S., & RichmanD.D.Antiretroviral drug resistance among patients recently infected with HIV. New England Journal of Medicine2002; 347: 385–394.
11.
SimonV., VanderhoevenJ., HurleyA., RamratnamB., LouieM., DawsonK., ParkinN., BodenD., & MarkowitzM.Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS2002; 16: 1511–1520.
12.
HarriganP.R., HertogsK., VerbiestW., PauwelsR., LarderB., KempS., BloorS., YipB., HoggR., AlexanderC., & MontanerJ.S.Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS1999; 13: 1863–1871.
13.
DeGruttolaV., DixL., D'AquilaR., HolderD., PhillipsA., Ait-KhaledM., BaxterJ., ClevenberghP., HammerS., HarriganR., KatzensteinD., LanierR., MillerM., ParaM., YerlyS., ZolopaA., MurrayJ., PatickA., MillerV., CastilloS., PedneaultL., & MellorsJ.The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy2000; 4: 41–48.
14.
BrownA.J., PreciousH.M., WhitcombJ.M., WongJ.K., QuiggM., HuangW., DaarE.S., D'AquilaR.T., KeiserP.H., ConnickE., HellmannN.S., PetropoulosC.J., RichmanD.D., & LittleS.J.Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to non-nucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. Journal of Virology2000; 74: 10269–10273.
15.
HarriganP.R., MontanerJ.S., WegnerS.A., VerbiestW., MillerV., WoodR., & LarderB.A.Worldwide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS2001; 15: 1671–1677.
16.
HoggR.S., YipB., ChanK.J., WoodE., CraibK.J., O'ShaughnessyM.V., & MontanerJ.S.Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. Journal of the American Medical Association2001; 286: 2568–2577.
17.
Low-BeerS., YipB., O'ShaughnessyM.V., HoggR.S., & MontanerJ.S.Adherence to triple therapy and viral load response. Journal of Acquired Immune Deficiency Syndrome2000; 23: 360–361.
18.
HoggR.S., HeathK., BangsbergD., YipB., PressN., O'ShaughnessyM.V., & MontanerJ.S.Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS2002; 16: 1051–1058.
19.
HertogsK., de BethuneM.P., MillerV., IvensT., SchelP., Van CauwenbergeA., Van Den EyndeC., Van GerwenV., AzijnH., Van HoutteM., PeetersF., StaszewskiS., ConantM., BloorS., KempS., LarderB., & PauwelsR.A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrobial Agents & Chemotherapy1998; 42: 269–276.
20.
NunbergJ.H., SchleifW.A., BootsE.J., O'BrienJ.A., QuinteroJ.C., HoffmanJ.M., EminiE.A., & GoldmanM.E.Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. Journal of Virology1998; 65: 4887–4892.
21.
RichmanD., ShihC.K., LowyI., RoseJ., ProdanovichP., GoffS., & GriffinJ.Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proceedings of the National Academy of Sciences, USA1991; 88: 11241–11245.
22.
MontanerJ.S., ReissP., CooperD., VellaS., HarrisM., ConwayB., WainbergM.A., SmithD., RobinsonP., HallD., MyersM., & LangeJ.M.A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. Journal of the American Medical Association1998; 279: 930–937.
23.
StaszewskiS., Morales-RamirezJ., TashimaK.T., RachlisA., SkiestD., StanfordJ., StrykerR., JohnsonP., LabriolaD.F., FarinaD., ManionD.J., & RuizN.M.Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New England Journal of Medicine1999; 341: 1865–1873.
24.
WhitcombJ.M., HuangW., LimoliK., PaxinosE., WrinT., SkowronG., DeeksS.G., BatesM., HellmannN.S., & PetropoulosC.J.Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS2002; 16: F41–F47.
25.
ShulmanN., ZolopaA.R., PassaroD., ShaferR.W., HuangW., KatzensteinD., IsraelskiD.M., HellmannN., PetropoulosC., & WhitcombJ.Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS2001; 15: 1125–1132.
